bioRxiv · 10.1101/2020.08.19.257725
A robust and versatile nanobody platform for drug delivery
Abstract
Therapeutic and diagnostic efficacies of numerous small biomolecules and chemical compounds are hampered by the short half-lives. Here we report the development of a repertoire of diverse, high-affinity albumin-nanobodies (NbHSA) to facilitate drug delivery. By integrating biophysics, and hybrid structural biology, we have systematically characterized the NbHSA for albumin binding, mapped the epitopes, and resolved the architecture of a tetrameric Nb-albumin complex. We employed quantitative proteomics for accurate, multiplex Nb pharmacokinetic analysis. Using a humanized albumin mouse model, we found that the NbHSA has outstanding pharmacokinetics; the most stable NbHSA has a 771-fold T1/2 improvement compared with a control Nb. Interestingly, the pharmacokinetics of NbHSA is related to their biophysical and structural properties. To demonstrate the utility of NbHSA, we developed a highly stable NbHSA-hIL-2 cytokine conjugate "Duraleukin" and confirmed its improved anticancer properties than hIL-2 alone. We envision that this high-quality Nb resource will advance research into novel biotherapeutics.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Shen, Z., Xiang, Y., Vergara, S., Chen, A., Xiao, Z., Santiago, U., Jin, C., Sang, Z., Luo, J., Chen, K., Schneidman-Duhovny, D., Camacho, C. J., Calero, G., Hu, B., Shi, Y.. 2020-08-20. A robust and versatile nanobody platform for drug delivery. https://doi.org/10.1101/2020.08.19.257725
Cite the original work for its findings. Save a collection to share your selection of sources.